Equillium (EQ) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Equillium (EQ) has outperformed Nkarta (NKTX) over the past year, gaining 10.4% versus a loss of 36.9%. Over five years, EQ leads with a -80.4% price change compared with -93.0% for NKTX. Equillium is the larger company by market cap ($87.3 million vs $81.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | NKTX |
|---|---|---|
| Share price | $1.06 | $1.14 |
| Market cap | $87.26M | $81.29M |
| 1-day change | -5.36% | +1.34% |
| YTD return | -31.61% | -38.65% |
| 1-year return | +10.42% | -36.94% |
| 5-year return | -80.41% | -93.05% |
| EPS (TTM) | $-0.12 | $-1.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-22.40M | $-104.08M |
| 52-week high | $3.54 | $3.72 |
| 52-week low | $0.81 | $1.11 |
| Distance from 52-week high | -70.06% | -69.49% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +707.55% | +825.11% |
| Average volume | 544.39K | 1.02M |
| Shares outstanding | 82.32M | 71.62M |
| Employees | 14 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed NKTX by 47.4 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 108 employees
EQ vs NKTX FAQ
Which is bigger, Equillium or Nkarta?
Equillium (EQ) is larger, with a market capitalization of $87.26M compared with $81.29M for Nkarta (NKTX).
Which stock has performed better over the past year, EQ or NKTX?
EQ returned +10.42% over the past 12 months, compared with -36.94% for NKTX (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.